|

A Long-Term Follow-up Study of the Severe Parkinson's Disease Patients Administered the IPS101A Gene Therapy Product.

RECRUITINGSponsored by Innopeutics Corporation
Actively Recruiting
SponsorInnopeutics Corporation
Started2026-05-29
Est. completion2031-07-30
Eligibility
Age50 Years – 80 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07629115

Summary

The purpose of this study is to evaluate the long-term safety of IPS101A and to assess the durability of efficacy in subjects who received IPS101A.

Eligibility

Age: 50 Years – 80 YearsHealthy volunteers accepted
Inclusion Criteria

* Subjects who were enrolled in the IPS101A-10 clinical trial and received IPS101A.
* Subjects and/or their legally acceptable representatives who voluntarily provided written informed consent to participate in this long-term follow-up study after being fully informed of the study, and who agreed to comply with all study-related requirements.

Exclusion Criteria

* Subjects who decline to provide consent for participation in the long-term follow-up study, or for whom follow-up assessments are not feasible due to death or other reasons.
* Subjects who, in the judgment of the investigator, are considered unsuitable for participation in the study due to unwillingness or inability to comply with scheduled study visits or other study-related requirements.

Conditions2

Parkinson DiseaseParkinson's Disease

Browse More Trials

Parkinson's Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.